US Stocks

Mirati Therapeutics, Inc.

Mirati Therapeutics is a California-based clinical-stage oncology company that develops therapies for cancer treatment. Its ongoing projects include MRTX849, a KRAS G12C inhibitor in Phase 1/2 clinical trial, and Sitravatinib, a spectrum-selective kinase inhibitor for Phase 3 clinical trials. The company has a collaboration with BeiGene, Ltd. for the development, manufacturing, and commercialization of Sitravatinib.